

# Durable Molecular Remissions in Chronic Lymphocytic Chimeric Antigen Receptor-Modified T Cells After Fa

Journal of Clinical Oncology

35, 3010-3020

DOI: [10.1200/jco.2017.72.8519](https://doi.org/10.1200/jco.2017.72.8519)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics. <i>Oncolimmunology</i> , 2017, 6, e1386829.	2.1	209
2	Immuno-oncology in urothelial carcinoma: who or what will ultimately sit on the iron throne?. <i>Immunotherapy</i> , 2017, 9, 951-954.	1.0	5
3	Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives. <i>Current Research in Translational Medicine</i> , 2017, 65, 93-102.	1.2	85
4	After ibrutinib, CAR T cells induce responses. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 588-588.	12.5	3
6	Ibrutinib as a bridge to transplant in high-risk chronic lymphocytic leukemia: A case report and review of the literature. <i>Leukemia Research Reports</i> , 2017, 8, 21-23.	0.2	1
7	Cancer Immunotherapy with Chimeric Antigen Receptor (CAR) T Cells. <i>Journal of Onco-Nephrology</i> , 2017, 1, 151-155.	0.3	4
8	How should we sequence and combine novel therapies in CLL?. <i>Hematology American Society of Hematology Education Program</i> , 2017, 2017, 346-353.	0.9	18
9	CAR-T Cells: Next Generation Cancer Therapeutics. <i>Journal of the Indian Institute of Science</i> , 2018, 98, 21-31.	0.9	0
10	T-cell Immunotherapies and the Role of Nonclinical Assessment: The Balance between Efficacy and Pathology. <i>Toxicologic Pathology</i> , 2018, 46, 131-146.	0.9	12
11	Chimeric Antigen Receptorâ€”Cell Therapy. <i>HemaSphere</i> , 2018, 2, e18.	1.2	30
12	The Pharmacology of T Cell Therapies. <i>Molecular Therapy - Methods and Clinical Development</i> , 2018, 8, 210-221.	1.8	78
13	The application of CAR-T cell therapy in hematological malignancies: advantages and challenges. <i>Acta Pharmaceutica Sinica B</i> , 2018, 8, 539-551.	5.7	141
14	Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy. <i>Current Research in Translational Medicine</i> , 2018, 66, 50-52.	1.2	100
15	Chimeric antigen receptor T cell therapy for non-Hodgkin lymphoma. <i>Current Research in Translational Medicine</i> , 2018, 66, 43-49.	1.2	45
16	Considerations for Clinical Review of Cellular Therapy Products: Perspectives of the China Food and Drug Administration Center for Drug Evaluation. <i>Human Gene Therapy</i> , 2018, 29, 121-127.	1.4	7
17	Treatment of Relapsed/Refractory Patients with Multiple Myeloma. <i>Hematologic Malignancies</i> , 2018, , 73-96.	0.2	1
18	Cancer immunotherapy beyond immune checkpoint inhibitors. <i>Journal of Hematology and Oncology</i> , 2018, 11, 8.	6.9	174
19	Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 218-218.	12.5	93

#	ARTICLE	IF	CITATIONS
20	CD19-specific chimeric antigen receptor-modified (CAR)-T cell therapy for the treatment of chronic lymphocytic leukemia in the ibrutinib era. <i>Immunotherapy</i> , 2018, 10, 251-254.	1.0	5
21	Chimeric antigen receptor T-cell therapy for cancer: a basic research-oriented perspective. <i>Immunotherapy</i> , 2018, 10, 221-234.	1.0	7
22	Reprint of: Building a Safer and Faster CAR: Seatbelts, Airbags, and CRISPR. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S15-S19.	2.0	12
23	Chimeric Antigen Receptor T Cell Therapy: Challenges to Bench-to-Bedside Efficacy. <i>Journal of Immunology</i> , 2018, 200, 459-468.	0.4	155
24	Chimeric antigen receptor-modified T cells: CD19 and the road beyond. <i>Blood</i> , 2018, 131, 2621-2629.	0.6	126
25	Introduction to a review series on emerging immunotherapies for hematologic diseases. <i>Blood</i> , 2018, 131, 2617-2620.	0.6	7
26	Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway. <i>Journal of Hematology and Oncology</i> , 2018, 11, 46.	6.9	53
27	Applications of Gene Editing Technologies to Cellular Therapies. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1537-1545.	2.0	3
28	Off the shelf T cell therapies for hematologic malignancies. <i>Best Practice and Research in Clinical Haematology</i> , 2018, 31, 166-175.	0.7	24
29	Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy. <i>Blood</i> , 2018, 131, 121-130.	0.6	374
30	Building a Safer and Faster CAR: Seatbelts, Airbags, and CRISPR. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 27-31.	2.0	49
31	Concurrent therapy of chronic lymphocytic leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia utilizing CD19-targeted CAR T-cells. <i>Leukemia and Lymphoma</i> , 2018, 59, 1717-1721.	0.6	6
32	Concise Review: Emerging Principles from the Clinical Application of Chimeric Antigen Receptor T Cell Therapies for B Cell Malignancies. <i>Stem Cells</i> , 2018, 36, 36-44.	1.4	48
33	Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 47-62.	12.5	1,659
34	Building upon the success of CART19: chimeric antigen receptor T cells for hematologic malignancies. <i>Leukemia and Lymphoma</i> , 2018, 59, 2040-2055.	0.6	10
35	Preclinical Optimization of a CD20-specific Chimeric Antigen Receptor Vector and Culture Conditions. <i>Journal of Immunotherapy</i> , 2018, 41, 19-31.	1.2	23
36	Optimal management of the young patient CLL patient. <i>Best Practice and Research in Clinical Haematology</i> , 2018, 31, 73-82.	0.7	1
37	CAR-T cell therapy, a door is open to find innumerable possibilities of treatments for cancer patients. <i>Turkish Journal of Haematology</i> , 2018, 35, 217-228.	0.2	9

#	ARTICLE	IF	CITATIONS
38	Current trends in the management of Richter's syndrome. International Journal of Hematologic Oncology, 2018, 7, IJH09.	0.7	42
40	Cytokine release syndrome and neurotoxicity after <sc>CD</sc>19 chimeric antigen receptor-modified (<sc>CAR</sc>) T cell therapy. British Journal of Haematology, 2018, 183, 364-374.	1.2	131
41	Genetic engineering of T cells with chimeric antigen receptors for hematological malignancy immunotherapy. Science China Life Sciences, 2018, 61, 1320-1332.	2.3	11
42	Chimeric antigen receptor-modified T cell therapy in chronic lymphocytic leukemia. Journal of Hematology and Oncology, 2018, 11, 130.	6.9	25
43	33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018). , 2018, 6, 114.		41
44	Overcoming Target Driven Fratricide for T Cell Therapy. Frontiers in Immunology, 2018, 9, 2940.	2.2	26
45	Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance. , 2018, 6, 137.		182
46	Targeted Therapies in CLL: Monotherapy Versus Combination Approaches. Current Hematologic Malignancy Reports, 2018, 13, 525-533.	1.2	9
47	Flow cytometric assays for identity, safety and potency of cellular therapies. Cytometry Part B - Clinical Cytometry, 2018, 94, 725-735.	0.7	13
48	Chronic lymphocytic leukemia treatment algorithm 2018. Blood Cancer Journal, 2018, 8, 93.	2.8	63
49	Hematopoietic Stem Cell Transplantation in the Era of Engineered Cell Therapy. Current Hematologic Malignancy Reports, 2018, 13, 484-493.	1.2	7
50	Tisagenlecleucel-T for the treatment of acute lymphocytic leukemia. Expert Opinion on Biological Therapy, 2018, 18, 1095-1106.	1.4	6
51	Non-viral therapeutic cell engineering with the Sleeping Beauty transposon system. Current Opinion in Genetics and Development, 2018, 52, 100-108.	1.5	41
52	Neurotoxicity Associated with CD19-Targeted CAR-T Cell Therapies. CNS Drugs, 2018, 32, 1091-1101.	2.7	175
53	Improving CLL cell fitness for cellular therapy by ex vivo activation and ibrutinib. Blood, 2018, 132, 2260-2272.	0.6	39
54	The biological basis and clinical symptoms of CAR-T therapy-associated toxicities. Cell Death and Disease, 2018, 9, 897.	2.7	90
55	On the front line: first choice pharmacotherapeutics for chronic lymphocytic leukemia. Expert Opinion on Pharmacotherapy, 2018, 19, 1675-1684.	0.9	0
56	Richter transformation in the era of novel agents. Hematology American Society of Hematology Education Program, 2018, 2018, 256-263.	0.9	31

#	ARTICLE	IF	CITATIONS
57	Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. <i>Nature Medicine</i> , 2018, 24, 739-748.	15.2	947
58	Evolution of CLL treatment “ from chemoimmunotherapy to targeted and individualized therapy. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 510-527.	12.5	114
59	Fludarabine and neurotoxicity in engineered T-cell therapy. <i>Gene Therapy</i> , 2018, 25, 176-191.	2.3	54
60	PiggyBac-Engineered T Cells Expressing CD19-Specific CARs that Lack IgG1 Fc Spacers Have Potent Activity against B-ALL Xenografts. <i>Molecular Therapy</i> , 2018, 26, 1883-1895.	3.7	43
61	Nanoparticles That Reshape the Tumor Milieu Create a Therapeutic Window for Effective T-cell Therapy in Solid Malignancies. <i>Cancer Research</i> , 2018, 78, 3718-3730.	0.4	83
62	Chimeric Antigen Receptor Therapy. <i>New England Journal of Medicine</i> , 2018, 379, 64-73.	13.9	1,488
63	Neuropathology of a Case With Fatal CAR T-Cell-Associated Cerebral Edema. <i>Journal of Neuropathology and Experimental Neurology</i> , 2018, 77, 877-882.	0.9	95
64	The promise of CAR T-cell therapy in aggressive B-cell lymphoma. <i>Best Practice and Research in Clinical Haematology</i> , 2018, 31, 293-298.	0.7	44
65	Differences in Expansion Potential of Naive Chimeric Antigen Receptor T Cells from Healthy Donors and Untreated Chronic Lymphocytic Leukemia Patients. <i>Frontiers in Immunology</i> , 2017, 8, 1956.	2.2	79
66	Advances on chimeric antigen receptor-modified T-cell therapy for oncotherapy. <i>Molecular Cancer</i> , 2018, 17, 91.	7.9	60
67	CARs versus BiTEs: A Comparison between T Cell “Redirection Strategies for Cancer Treatment. <i>Cancer Discovery</i> , 2018, 8, 924-934.	7.7	173
68	High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: integrating molecular and cellular therapies. <i>Blood</i> , 2018, 132, 892-902.	0.6	83
69	Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy. <i>Biomarker Research</i> , 2018, 6, 4.	2.8	184
70	Chronic Lymphocytic Leukemia: Diagnosis and Treatment. <i>Mayo Clinic Proceedings</i> , 2018, 93, 651-664.	1.4	42
71	A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era. <i>Blood</i> , 2018, 132, 521-532.	0.6	81
72	How and when I do allogeneic transplant in CLL. <i>Blood</i> , 2018, 132, 31-39.	0.6	49
73	A Phase I/IIa Trial Using CD19-Targeted Third-Generation CAR T Cells for Lymphoma and Leukemia. <i>Clinical Cancer Research</i> , 2018, 24, 6185-6194.	3.2	177
74	No longer too exhausted to run. <i>Blood</i> , 2018, 132, 464-465.	0.6	2

#	ARTICLE	IF	CITATIONS
75	Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function. <i>Science Signaling</i> , 2018, 11, .	1.6	323
76	Autologous CD19-Targeted CAR T Cells in Patients with Residual CLL following Initial Purine Analog-Based Therapy. <i>Molecular Therapy</i> , 2018, 26, 1896-1905.	3.7	65
77	Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 45-63.	12.5	178
78	Cancer immune therapy for lymphoid malignancies: recent advances. <i>Seminars in Immunopathology</i> , 2019, 41, 111-124.	2.8	15
79	Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working Parties. <i>Bone Marrow Transplantation</i> , 2019, 54, 44-52.	1.3	59
80	SOHO State of the Art Updates and Next Questions: T-Cellâ€œDirected Immune Therapies for Multiple Myeloma: Chimeric Antigen Receptorâ€œModified T Cells and Bispecific T-Cellâ€œEngaging Agents. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 537-544.	0.2	18
81	Cancer immunotherapy: Adoptive cell therapies, cytokine-related toxicities, and the kidneys. <i>Journal of Onco-Nephrology</i> , 2019, 3, 131-143.	0.3	0
82	Individual Patient Data Meta-Analysis from 16 Trials for Safety Factors in Cytokine Release Syndrome After CAR-T Therapy in Patients with Non-Hodgkin Lymphoma (NHL) and Acute Lymphoblastic Leukemia. <i>Advances in Therapy</i> , 2019, 36, 2881-2894.	1.3	8
83	State-of-the-art for CAR T-cell therapy for chronic lymphocytic leukemia in 2019. , 2019, 7, 202.		48
84	Pentostatin, Cyclophosphamide, and Rituximab Followed by Alemtuzumab for Relapsed or Refractory Chronic Lymphocytic Leukemia: A Phase 2 Trial of the ECOG-Acrin Cancer Research Group (E2903). <i>Acta Haematologica</i> , 2019, 142, 224-232.	0.7	6
85	How to Choose the Best Treatment and Testing for Chronic Lymphocytic Leukemia in the Tsunami of New Treatment Options. <i>Current Oncology Reports</i> , 2019, 21, 74.	1.8	4
86	Advances in drugâ€œbased therapies in chronic lymphocytic leukemia and future prospects. <i>Advances in Cell and Gene Therapy</i> , 2019, 2, e51.	0.6	0
87	Cellular therapy: Immuneâ€œrelated complications. <i>Immunological Reviews</i> , 2019, 290, 114-126.	2.8	55
88	Updates on CAR Tâ€œcell therapy in Bâ€œcell malignancies. <i>Immunological Reviews</i> , 2019, 290, 39-59.	2.8	61
89	Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment. <i>American Journal of Hematology</i> , 2019, 94, 1266-1287.	2.0	352
90	CD19 CAR T cells following autologous transplantation in poor-risk relapsed and refractory B-cell non-Hodgkin lymphoma. <i>Blood</i> , 2019, 134, 626-635.	0.6	59
91	High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy. <i>Blood</i> , 2019, 134, 636-640.	0.6	127
92	CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma: current status and perspectives. <i>Leukemia</i> , 2019, 33, 2767-2778.	3.3	47

#	ARTICLE	IF	CITATIONS
93	Reduced intensity conditioning regimens including alkylating chemotherapy do not alter survival outcomes after allogeneic hematopoietic cell transplantation in chronic lymphocytic leukemia compared to low-intensity non-myeloablative conditioning. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 2823-2834.	1.2	7
94	Minimal Residual Disease in Chronic Lymphocytic Leukemia: A New Goal?. <i>Frontiers in Oncology</i> , 2019, 9, 689.	1.3	41
95	CD3 bispecific antibody-induced cytokine release is dispensable for cytotoxic T cell activity. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	117
96	Engaging Cytotoxic T and NK Cells for Immunotherapy in Chronic Lymphocytic Leukemia. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4315.	1.8	21
97	Clinical lessons learned from the first leg of the CAR T cell journey. <i>Nature Medicine</i> , 2019, 25, 1341-1355.	15.2	400
99	Direct comparison of target-reactivity and cross-reactivity induced by CAR- and BiTE-redirected T cells for the development of antibody-based T-cell therapy. <i>Scientific Reports</i> , 2019, 9, 13293.	1.6	20
100	Î³-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma. <i>Blood</i> , 2019, 134, 1585-1597.	0.6	209
101	B-cell-specific IRF4 deletion accelerates chronic lymphocytic leukemia development by enhanced tumor immune evasion. <i>Blood</i> , 2019, 134, 1717-1729.	0.6	17
102	Defining precision cellular immunotherapy-seeking biomarkers to predict and optimize outcomes of T cell therapies in cancer. <i>Precision Cancer Medicine</i> , 2019, 2, 25-25.	1.8	1
104	Genetically Engineered T Cell Therapies and Immune System Engagers for Graft-Versus-Host Disease and Graft Versus Leukemia. , 2019, , 127-140.		0
106	New roles for B cell receptor associated kinases: when the B cell is not the target. <i>Leukemia</i> , 2019, 33, 576-587.	3.3	26
108	Allogeneic <sc>CD</sc>27-depleted cells in adoptive cell therapy. <i>Advances in Cell and Gene Therapy</i> , 2019, 2, e45.	0.6	1
109	Recent perspective on CAR and FcÎ³-CR T cell immunotherapy for cancers: Preclinical evidence versus clinical outcomes. <i>Biochemical Pharmacology</i> , 2019, 166, 335-346.	2.0	20
110	Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed/refractory CLL. <i>JCI Insight</i> , 2019, 4, .	2.3	71
111	The efficacy of anti-CD19 chimeric antigen receptor T cells for B-cell malignancies. <i>Cytotherapy</i> , 2019, 21, 769-781.	0.3	17
112	A review of chimeric antigen receptor T-cells in lymphoma. <i>Expert Review of Hematology</i> , 2019, 12, 551-561.	1.0	11
113	CAR T-cell therapy: Full speed ahead. <i>Hematological Oncology</i> , 2019, 37, 95-100.	0.8	131
114	Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector: a unicentre phase I/II clinical trial protocol. <i>BMJ Open</i> , 2019, 9, e026644.	0.8	27

#	ARTICLE	IF	CITATIONS
115	Limitations in the Design of Chimeric Antigen Receptors for Cancer Therapy. <i>Cells</i> , 2019, 8, 472.	1.8	122
116	Tumor-Specific Reactive Oxygen Species Accelerators Improve Chimeric Antigen Receptor T Cell Therapy in B Cell Malignancies. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2469.	1.8	14
117	Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8+ T cells and impede CAR T-cell efficacy. <i>Blood</i> , 2019, 134, 44-58.	0.6	118
118	Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 9543-9551.	3.3	266
119	Functional genomics in the era of cancer immunotherapy: challenges and clinical implications. <i>Briefings in Functional Genomics</i> , 2019, 18, 83-85.	1.3	0
120	Neurological toxicities associated with chimeric antigen receptor T-cell therapy. <i>Brain</i> , 2019, 142, 1334-1348.	3.7	166
121	Accelerating chimeric antigen receptor therapy in chronic lymphocytic leukemia: The development and challenges of chimeric antigen receptor T cell therapy for chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 2019, 94, S10-S17.	2.0	22
122	Inhibiting Bruton's Tyrosine Kinase in CLL and Other B-Cell Malignancies. <i>Targeted Oncology</i> , 2019, 14, 125-138.	1.7	33
123	Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor (CAR) T cell therapy. <i>Expert Review of Hematology</i> , 2019, 12, 195-205.	1.0	63
124	Chimeric antigen receptor T cell immunotherapy for multiple myeloma: A review of current data and potential clinical applications. <i>American Journal of Hematology</i> , 2019, 94, S28-S33.	2.0	35
125	Proliferation tracing with single-cell mass cytometry optimizes generation of stem cell memory-like T cells. <i>Nature Biotechnology</i> , 2019, 37, 259-266.	9.4	49
126	Hematopoietic Stem Cell Transplant and Cellular Therapy. , 2019, , 109-158.		1
127	The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells. <i>Blood</i> , 2019, 133, 1876-1887.	0.6	230
128	Toxicities of CD19 CAR T cell immunotherapy. <i>American Journal of Hematology</i> , 2019, 94, S42-S49.	2.0	102
129	Gene-based Interventions for Cancer Immunotherapy. , 0, , .		0
131	Clinical care of chimeric antigen receptor T-cell patients and managing immune-related adverse effects in the ambulatory and hospitalized setting: a review. <i>Future Oncology</i> , 2019, 15, 4235-4246.	1.1	5
132	EVOLVING ROLE OF CAR T-CELL IN CANCER IMMUNOTHERAPY. <i>International Journal of Current Pharmaceutical Research</i> , 0, , 19-27.	0.2	0
133	Fludarabine exposure in the conditioning prior to allogeneic hematopoietic cell transplantation predicts outcomes. <i>Blood Advances</i> , 2019, 3, 2179-2187.	2.5	42



#	ARTICLE	IF	CITATIONS
134	Distinct immune composition in lymph node and peripheral blood of CLL patients is reshaped during venetoclax treatment. <i>Blood Advances</i> , 2019, 3, 2642-2652.	2.5	79
135	Safety of allogeneic hematopoietic cell transplant in adults after CD19-targeted CAR T-cell therapy. <i>Blood Advances</i> , 2019, 3, 3062-3069.	2.5	74
136	Durable preservation of antiviral antibodies after CD19-directed chimeric antigen receptor T-cell immunotherapy. <i>Blood Advances</i> , 2019, 3, 3590-3601.	2.5	52
138	Overcoming Ibrutinib Resistance in Chronic Lymphocytic Leukemia. <i>Cancers</i> , 2019, 11, 1834.	1.7	32
139	A highly soluble Sleeping Beauty transposase improves control of gene insertion. <i>Nature Biotechnology</i> , 2019, 37, 1502-1512.	9.4	63
141	Management of T-Cell Engaging Immunotherapy Complications. <i>Cancer Journal (Sudbury, Mass )</i> , 2019, 25, 223-230.	1.0	15
142	Enterotoxins can support CAR T cells against solid tumors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 25229-25235.	3.3	16
143	Chimeric Antigen Receptor T Cells Targeting CD19 and Ibrutinib for Chronic Lymphocytic Leukemia. <i>HemaSphere</i> , 2019, 3, e174.	1.2	5
144	Emerging treatment options for patients with p53-pathway-deficient CLL. <i>Therapeutic Advances in Hematology</i> , 2019, 10, 204062071989135.	1.1	14
145	From Biology to Therapy: The CLL Success Story. <i>HemaSphere</i> , 2019, 3, e175.	1.2	55
146	In the Eye of the Storm: Immune-mediated Toxicities Associated With CAR T Cell Therapy. <i>HemaSphere</i> , 2019, 3, e191.	1.2	80
147	The evolving treatment landscape of chronic lymphocytic leukemia. <i>Current Opinion in Oncology</i> , 2019, 31, 568-573.	1.1	15
148	Next Generation of Cancer Treatments: Chimeric Antigen Receptor T-Cell Therapy and Its Related Toxicities: A Review for Perioperative Physicians. <i>Anesthesia and Analgesia</i> , 2019, 129, 434-441.	1.1	11
149	Chimeric Antigen Receptor T Cells in Chronic Lymphocytic Leukemia. <i>Cancer Journal (Sudbury, Mass )</i> , 2019, 25, 436-441.	1.0	2
150	Understanding the Mechanisms of Resistance to CAR T-Cell Therapy in Malignancies. <i>Frontiers in Oncology</i> , 2019, 9, 1237.	1.3	106
151	Minimal Residual Disease Assessment in CLL: Ready for Use in Clinical Routine?. <i>HemaSphere</i> , 2019, 3, e287.	1.2	33
152	Principles of adoptive T cell therapy in cancer. <i>Seminars in Immunopathology</i> , 2019, 41, 49-58.	2.8	141
153	In Vivo PET Tracking of <sup>89</sup> Zr-Labeled <sup>19</sup> F-Labelled CAR T Cells to Mouse Xenograft Breast Tumors Activated with Liposomal Alendronate. <i>Molecular Therapy</i> , 2019, 27, 219-229.	3.7	89

#	ARTICLE	IF	CITATIONS
154	Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management. <i>Blood Reviews</i> , 2019, 34, 45-55.	2.8	570
155	CAR <sup>+</sup> cells beyond CD19, UnCAR <sup>+</sup> ed territory. <i>American Journal of Hematology</i> , 2019, 94, S34-S41.	2.0	6
156	Assessment of older adult candidates for allogeneic hematopoietic cell transplantation: updates and remaining questions. <i>Expert Review of Hematology</i> , 2019, 12, 99-106.	1.0	5
157	Emerging Cellular Therapies for Cancer. <i>Annual Review of Immunology</i> , 2019, 37, 145-171.	9.5	263
158	Most Recent Clinical Advances in CAR T Cell and Gene Therapy 2017/2018. <i>Advances and Controversies in Hematopoietic Transplantation and Cell Therapy</i> , 2019, , 3-24.	0.0	0
159	Chimeric Antigen Receptor-T Cells for Leukemias in Adults: Methods, Data and Challenges. <i>Advances and Controversies in Hematopoietic Transplantation and Cell Therapy</i> , 2019, , 75-92.	0.0	0
160	Chimeric Antigen Receptor T Cells for Lymphomas: Methods, Data, and Challenges. <i>Advances and Controversies in Hematopoietic Transplantation and Cell Therapy</i> , 2019, , 93-108.	0.0	0
161	Patient-Reported Outcomes with Chimeric Antigen Receptor T Cell Therapy: Challenges and Opportunities. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e155-e162.	2.0	56
162	Clinical characteristics and outcomes of Richter transformation: experience of 204 patients from a single center. <i>Haematologica</i> , 2020, 105, 765-773.	1.7	64
163	Adverse Events of Novel Therapies for Hematologic Malignancies: What Emergency Physicians Should Know. <i>Annals of Emergency Medicine</i> , 2020, 75, 264-286.	0.3	3
164	Patient-Reported Neuropsychiatric Outcomes of Long-Term Survivors after Chimeric Antigen Receptor T Cell Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 34-43.	2.0	93
165	Adeno <sup>+</sup> Associated Viral Vectors for Homology <sup>+</sup> Directed Generation of CAR <sup>+</sup> Cells. <i>Biotechnology Journal</i> , 2020, 15, e1900286.	1.8	9
166	Late Events after Treatment with CD19-Targeted Chimeric Antigen Receptor Modified T Cells. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 26-33.	2.0	222
167	Rituximab-based allogeneic transplant for chronic lymphocytic leukemia with comparison to historical experience. <i>Bone Marrow Transplantation</i> , 2020, 55, 172-181.	1.3	10
168	Pretransplant active disease status and HLA class II mismatching are associated with increased incidence and severity of cytokine release syndrome after haploidentical transplantation with posttransplant cyclophosphamide. <i>Cancer Medicine</i> , 2020, 9, 52-61.	1.3	13
169	Determinants of response and resistance to CAR T cell therapy. <i>Seminars in Cancer Biology</i> , 2020, 65, 80-90.	4.3	59
170	Multiple B cell malignancies in patients with chronic lymphocytic leukemia: epidemiology, pathology, and clinical implications. <i>Leukemia and Lymphoma</i> , 2020, 61, 1037-1051.	0.6	4
171	Clonal kinetics and single-cell transcriptional profiling of CAR-T cells in patients undergoing CD19 CAR-T immunotherapy. <i>Nature Communications</i> , 2020, 11, 219.	5.8	167

#	ARTICLE	IF	CITATIONS
172	Late Psychiatric and Neurocognitive Effects of Chimeric Antigen Receptor T Cell Therapy Warrant Further Investigation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e3-e4.	2.0	2
173	Ibrutinib as a salvage therapy after allogeneic HCT for chronic lymphocytic leukemia. <i>Bone Marrow Transplantation</i> , 2020, 55, 884-890.	1.3	13
174	Nitinol thin films functionalized with CAR-T cells for the treatment of solid tumours. <i>Nature Biomedical Engineering</i> , 2020, 4, 195-206.	11.6	70
175	Anti-BCMA CAR T-cell therapy in multiple myeloma: can we do better?. <i>Leukemia</i> , 2020, 34, 21-34.	3.3	117
176	Development and verification of a nomogram for prediction of recurrence-free survival in clear cell renal cell carcinoma. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 1245-1255.	1.6	7
177	Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). <i>Haematologica</i> , 2020, 105, 297-316.	1.7	230
178	B cell maturation antigen-specific chimeric antigen receptor T cells for relapsed or refractory multiple myeloma: A meta-analysis. <i>European Journal of Haematology</i> , 2020, 104, 318-327.	1.1	41
179	Harnessing the Effects of BTKi on T Cells for Effective Immunotherapy against CLL. <i>International Journal of Molecular Sciences</i> , 2020, 21, 68.	1.8	34
180	Management of Cytokine Release Syndrome. , 2020, , 45-64.		1
181	Neurotoxicities After CAR T-Cell Immunotherapy. , 2020, , 83-105.		7
182	Cord-Blood Natural Killer Cell-Based Immunotherapy for Cancer. <i>Frontiers in Immunology</i> , 2020, 11, 584099.	2.2	20
183	Single-Cell Analyses Identify Brain Mural Cells Expressing CD19 as Potential Off-Tumor Targets for CAR-T Immunotherapies. <i>Cell</i> , 2020, 183, 126-142.e17.	13.5	269
185	A Concise Review of Neurologic Complications Associated with Chimeric Antigen Receptor T-cell Immunotherapy. <i>Neurologic Clinics</i> , 2020, 38, 953-963.	0.8	14
186	Iatrogenic Neuropathology of Systemic Therapies. <i>Surgical Pathology Clinics</i> , 2020, 13, 331-342.	0.7	4
187	Potential strategies against resistance to CAR T-cell therapy in haematological malignancies. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592096296.	1.4	7
188	Assessment of CAR T Cell Frequencies in Axicabtagene Ciloleucel and Tisagenlecleucel Patients Using Duplex Quantitative PCR. <i>Cancers</i> , 2020, 12, 2820.	1.7	13
189	Immune recovery in patients with mantle cell lymphoma receiving long-term ibrutinib and venetoclax combination therapy. <i>Blood Advances</i> , 2020, 4, 4849-4859.	2.5	14
190	Co-expressing LRP6 With Anti-CD19 CAR-T Cells for Improved Therapeutic Effect Against B-ALL. <i>Frontiers in Oncology</i> , 2020, 10, 1346.	1.3	5

#	ARTICLE	IF	CITATIONS
191	Allogeneic Transplantation and Chimeric Antigen Receptor-Engineered T-Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2020, 34, 957-970.	0.9	6
192	Axicabtagene ciloleucel for relapsed or refractory lymphoma after prior treatment with a different CD19-directed CAR T-cell therapy. <i>Blood Advances</i> , 2020, 4, 4869-4872.	2.5	12
193	Manufacturing of natural killer cells for treating solid malignancies. <i>Journal of Immunology and Regenerative Medicine</i> , 2020, 10, 100031.	0.2	0
194	Humanized Mice Are Precious Tools for Preclinical Evaluation of CAR T and CAR NK Cell Therapies. <i>Cancers</i> , 2020, 12, 1915.	1.7	30
195	Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity. <i>Journal of Clinical Oncology</i> , 2020, 38, 3095-3106.	0.8	216
196	Mechanisms of ibrutinib resistance in chronic lymphocytic leukemia and alternative treatment strategies. <i>Expert Review of Hematology</i> , 2020, 13, 871-883.	1.0	8
197	Gene Modified CAR-T Cellular Therapy for Hematologic Malignancies. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8655.	1.8	13
198	Current Treatment of Refractory/Relapsed Chronic Lymphocytic Leukemia: A Focus on Novel Drugs. <i>Acta Haematologica</i> , 2021, 144, 365-379.	0.7	13
199	Evolution of Advanced Chronic Lymphoid Leukemia Unveiled by Single-Cell Transcriptomics: A Case Report. <i>Frontiers in Oncology</i> , 2020, 10, 584607.	1.3	0
200	Clinical activity of axicabtagene ciloleucel in adult patients with Richter syndrome. <i>Blood Advances</i> , 2020, 4, 4648-4652.	2.5	53
201	C(h)AR-ting a new course in incurable lymphomas: CAR T cells for mantle cell and follicular lymphomas. <i>Blood Advances</i> , 2020, 4, 5858-5862.	2.5	12
202	Standard treatment approaches for relapsed/refractory chronic lymphocytic leukemia after frontline chemoimmunotherapy. <i>Hematology American Society of Hematology Education Program</i> , 2020, 2020, 33-40.	0.9	9
203	Approaches for relapsed CLL after chemotherapy-free frontline regimens. <i>Hematology American Society of Hematology Education Program</i> , 2020, 2020, 10-17.	0.9	8
204	Clinical Predictors of Neurotoxicity After Chimeric Antigen Receptor T-Cell Therapy. <i>JAMA Neurology</i> , 2020, 77, 1536.	4.5	68
205	The model of cytokine release syndrome in CAR T-cell treatment for B-cell non-Hodgkin lymphoma. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 134.	7.1	84
206	Refractory and 17p-deleted chronic lymphocytic leukemia: improving survival with pathway inhibitors and allogeneic stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e256-e262.	2.0	4
207	Tailoring precision immunotherapy: coming to a clinic soon?. <i>ESMO Open</i> , 2020, 5, e000631.	2.0	8
208	Allogeneic hematopoietic cell transplantation after prior targeted therapy for high-risk chronic lymphocytic leukemia. <i>Blood Advances</i> , 2020, 4, 4113-4123.	2.5	22

#	ARTICLE	IF	CITATIONS
209	BCMA-targeted immunotherapy for multiple myeloma. <i>Journal of Hematology and Oncology</i> , 2020, 13, 125.	6.9	108
210	Synergistic effect of ibrutinib and CD19 CAR-T cells on Raji cells in vivo and in vitro. <i>Cancer Science</i> , 2020, 111, 4051-4060.	1.7	19
211	Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents. <i>Blood Advances</i> , 2020, 4, 3977-3989.	2.5	55
212	Overcoming the Hurdles of Autologous T-Cell-Based Therapies in B-Cell Non-Hodgkin Lymphoma. <i>Cancers</i> , 2020, 12, 3837.	1.7	9
213	Pre-sensitization of Malignant B Cells Through Venetoclax Significantly Improves the Cytotoxic Efficacy of CD19.CAR-T Cells. <i>Frontiers in Immunology</i> , 2020, 11, 608167.	2.2	23
214	Immune Dysfunctions and Immune-Based Therapeutic Interventions in Chronic Lymphocytic Leukemia. <i>Frontiers in Immunology</i> , 2020, 11, 594556.	2.2	39
215	Toxicities of Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma: An Overview of Experience From Clinical Trials, Pathophysiology, and Management Strategies. <i>Frontiers in Immunology</i> , 2020, 11, 620312.	2.2	21
216	The Application of CAR-T Cells in Haematological Malignancies. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2020, 68, 34.	1.0	19
217	Are Autologous Stem Cell Transplants Still Required to Treat Myeloma in the Era of Novel Therapies? A Review from the Chronic Malignancies Working Party of the EBMT. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1559-1566.	2.0	6
218	Biomarkers in individualized management of chimeric antigen receptor T cell therapy. <i>Biomarker Research</i> , 2020, 8, 13.	2.8	23
219	Advances in CAR T Therapy for Hematologic Malignancies. <i>Pharmacotherapy</i> , 2020, 40, 741-755.	1.2	11
220	Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure. <i>Blood</i> , 2020, 135, 1650-1660.	0.6	222
221	Chronic lymphocytic leukemia in 2020: a surfeit of riches?. <i>Leukemia</i> , 2020, 34, 1979-1983.	3.3	4
222	Transposon-Based CAR T Cells in Acute Leukemias: Where Are We Going?. <i>Cells</i> , 2020, 9, 1337.	1.8	32
223	A Cross-Reactive Small Protein Binding Domain Provides a Model to Study Off-Tumor CAR-T Cell Toxicity. <i>Molecular Therapy - Oncolytics</i> , 2020, 17, 278-292.	2.0	9
224	Investigational treatments for chronic lymphocytic leukemia: a focus on phase 1 and 2 clinical trials. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 709-722.	1.9	6
225	CAR-T and ibrutinib vs CLL: sequential or simultaneous?. <i>Blood</i> , 2020, 135, 1611-1612.	0.6	6
226	T-cells in chronic lymphocytic leukemia: Guardians or drivers of disease?. <i>Leukemia</i> , 2020, 34, 2012-2024.	3.3	70

#	ARTICLE	IF	CITATIONS
227	Ibrutinib Resistance Mechanisms and Treatment Strategies for B-Cell Lymphomas. <i>Cancers</i> , 2020, 12, 1328.	1.7	65
228	CAR T-cell immunotherapy of B-cell malignancy: the story so far. , 2020, 8, 251513552092716.	1.4	30
229	Development of CAR-T cell therapies for multiple myeloma. <i>Leukemia</i> , 2020, 34, 2317-2332.	3.3	68
230	Ibrutinib in Chronic Lymphocytic Leukemia: Clinical Applications, Drug Resistance, and Prospects. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 4877-4892.	1.0	19
231	The Advent of CAR T-Cell Therapy for Lymphoproliferative Neoplasms: Integrating Research Into Clinical Practice. <i>Frontiers in Immunology</i> , 2020, 11, 888.	2.2	45
232	CAR T-Cell Therapy for B-Cell non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia: Clinical Trials and Real-World Experiences. <i>Frontiers in Oncology</i> , 2020, 10, 849.	1.3	62
233	Efficacy of minimal residual disease driven immune-intervention after allogeneic hematopoietic stem cell transplantation for high-risk chronic lymphocytic leukemia: results of a prospective multicenter trial. <i>Haematologica</i> , 2021, 106, 1867-1875.	1.7	7
234	Potential Role of Anti-interleukin (IL)-6 Drugs in the Treatment of COVID-19: Rationale, Clinical Evidence and Risks. <i>BioDrugs</i> , 2020, 34, 415-422.	2.2	50
235	Clinical outcome and prognostic factors of patients with Richter syndrome: real-world study of the Spanish Chronic Lymphocytic Leukemia Study Group (GELLC). <i>British Journal of Haematology</i> , 2020, 190, 854-863.	1.2	36
236	Novel Therapies in Chronic Lymphocytic Leukemia: A Rapidly Changing Landscape. <i>Current Treatment Options in Oncology</i> , 2020, 21, 24.	1.3	40
237	Chronic Lymphocytic Leukaemia in 2020: the Future Has Arrived. <i>Current Oncology Reports</i> , 2020, 22, 36.	1.8	23
238	Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy. <i>Clinical Cancer Research</i> , 2020, 26, 3589-3596.	3.2	80
239	Optimized Assessment of qPCR-Based Vector Copy Numbers as a Safety Parameter for GMP-Grade CAR T Cells and Monitoring of Frequency in Patients. <i>Molecular Therapy - Methods and Clinical Development</i> , 2020, 17, 448-454.	1.8	28
240	Use of CAR-T cell therapy, PD-1 blockade, and their combination for the treatment of hematological malignancies. <i>Clinical Immunology</i> , 2020, 214, 108382.	1.4	40
241	Recognizing and Grading CAR T-Cell Toxicities: An Advanced Practitioner Perspective. <i>Frontiers in Oncology</i> , 2020, 10, 885.	1.3	20
242	Neurological Complications of CAR T Cell Therapy. <i>Current Oncology Reports</i> , 2020, 22, 83.	1.8	16
243	Next-Generation Manufacturing Protocols Enriching TSCM CAR T Cells Can Overcome Disease-Specific T Cell Defects in Cancer Patients. <i>Frontiers in Immunology</i> , 2020, 11, 1217.	2.2	69
244	CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas. <i>Blood</i> , 2020, 136, 2308-2318.	0.6	133

#	ARTICLE	IF	CITATIONS
245	Toxicities of novel therapies for hematologic malignancies. <i>Expert Review of Hematology</i> , 2020, 13, 241-257.	1.0	2
246	Chimeric Antigen Receptor-T-Cell Therapy for B-Cell Hematological Malignancies: An Update of the Pivotal Clinical Trial Data. <i>Pharmaceutics</i> , 2020, 12, 194.	2.0	40
247	Controlling Cytokine Release Syndrome to Harness the Full Potential of CAR-Based Cellular Therapy. <i>Frontiers in Oncology</i> , 2020, 9, 1529.	1.3	23
248	The up-to-date role of biologics for the treatment of chronic lymphocytic leukemia. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 799-812.	1.4	5
249	All systems go: converging synthetic biology and combinatorial treatment for CAR-T cell therapy. <i>Current Opinion in Biotechnology</i> , 2020, 65, 75-87.	3.3	33
250	A review of cancer immunotherapy toxicity. <i>Ca-A Cancer Journal for Clinicians</i> , 2020, 70, 86-104.	157.7	753
251	Immunotherapy Approaches for Pediatric CNS Tumors and Associated Neurotoxicity. <i>Pediatric Neurology</i> , 2020, 107, 7-15.	1.0	2
252	Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology. <i>Oncolimmunology</i> , 2020, 9, 1703449.	2.1	156
253	CAR T Cell Generation by piggyBac Transposition from Linear Doggybone DNA Vectors Requires Transposon DNA-Flanking Regions. <i>Molecular Therapy - Methods and Clinical Development</i> , 2020, 17, 359-368.	1.8	22
254	Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. <i>New England Journal of Medicine</i> , 2020, 382, 545-553.	13.9	1,252
255	CAR T-cell therapy for the management of refractory/relapsed high-grade B-cell lymphoma: a practical overview. <i>Bone Marrow Transplantation</i> , 2020, 55, 1525-1532.	1.3	17
256	Performance of anti-CD19 chimeric antigen receptor T cells in genetically defined classes of chronic lymphocytic leukemia. , 2020, 8, e000471.		8
257	Paving the Way toward Successful Multiple Myeloma Treatment: Chimeric Antigen Receptor T-Cell Therapy. <i>Cells</i> , 2020, 9, 983.	1.8	10
258	Long-Term Outcomes From a Randomized Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells in Relapsed Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2020, 38, 2862-2871.	0.8	102
259	Chronic Lymphocytic Leukemia. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2021, 11, a035220.	2.9	28
260	Potent CAR-T cells engineered with Sleeping Beauty transposon vectors display a central memory phenotype. <i>Gene Therapy</i> , 2021, 28, 3-5.	2.3	7
261	Revving the CAR "Combination strategies to enhance CAR T cell effectiveness. <i>Blood Reviews</i> , 2021, 45, 100695.	2.8	22
262	Allogeneic hematopoietic cell transplantation is an effective treatment for patients with Richter syndrome: A systematic review and meta-analysis. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2021, 14, 33-40.	0.6	17



#	ARTICLE	IF	CITATIONS
263	Clinical CAR-T Cell and Oncolytic Virotherapy for Cancer Treatment. <i>Molecular Therapy</i> , 2021, 29, 505-520.	3.7	48
264	Immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy for lymphoma: predictive biomarkers and clinical outcomes. <i>Neuro-Oncology</i> , 2021, 23, 112-121.	0.6	53
265	Toward Better Understanding and Management of CAR-T Cell-associated Toxicity. <i>Annual Review of Medicine</i> , 2021, 72, 365-382.	5.0	34
266	Ibrutinib for improved chimeric antigen receptor T cell production for chronic lymphocytic leukemia patients. <i>International Journal of Cancer</i> , 2021, 148, 419-428.	2.3	42
267	Nanotechnology-Based CAR-T Strategies for Improving Efficacy and Safety of Tumor Immunotherapy. <i>Advanced Functional Materials</i> , 2021, 31, .	7.8	13
268	Anti-CD19 CAR-T cells: Digging in the dark side of the golden therapy. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103096.	2.0	10
269	Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib: Development and Validation of a Four-Factor Prognostic Model. <i>Journal of Clinical Oncology</i> , 2021, 39, 576-585.	0.8	74
270	Pharmacology of Chimeric Antigen Receptor-Modified T Cells. <i>Annual Review of Pharmacology and Toxicology</i> , 2021, 61, 805-829.	4.2	7
271	Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies. <i>Blood</i> , 2021, 137, 323-335.	0.6	111
272	CAR T cell therapy in B-cell acute lymphoblastic leukaemia: Insights from mathematical models. <i>Communications in Nonlinear Science and Numerical Simulation</i> , 2021, 94, 105570.	1.7	20
273	A Bispecific Antibody Antagonizes Prosurvival CD40 Signaling and Promotes $\gamma\delta$ T cell-Mediated Antitumor Responses in Human B-cell Malignancies. <i>Cancer Immunology Research</i> , 2021, 9, 50-61.	1.6	23
274	The toxicity of cell therapy: Mechanism, manifestations, and challenges. <i>Journal of Applied Toxicology</i> , 2021, 41, 659-667.	1.4	7
275	Side-effect management of chimeric antigen receptor (CAR) T-cell therapy. <i>Annals of Oncology</i> , 2021, 32, 34-48.	0.6	231
276	Der Stand der Therapie bei der refraktären/rezidivierenden chronischen lymphatischen Leukämie: Neuartige Wirkstoffe im Fokus. <i>Karger Kompass Onkologie</i> , 2021, 8, 59-69.	0.0	0
277	Toxicities of Novel Antineoplastic Therapies. , 2021, , 711-738.		1
279	CAR-T Cells for the Treatment of Chronic Lymphocytic Leukemia: Literature Review. <i>Klinicheskaya Onkologematologiya/Clinical Oncohematology</i> , 2021, 14, 225-230.	0.1	2
280	Neurologic complications associated with CAR T-cell therapy. , 2021, , 381-388.		0
281	Overcoming resistance to targeted therapies in chronic lymphocytic leukemia. <i>Blood Advances</i> , 2021, 5, 334-343.	2.5	32



#	ARTICLE	IF	CITATIONS
282	Potency analysis of cellular therapies: the role of molecular assays. , 2021, , 49-70.		0
283	Generating CAR T cells from tumor-infiltrating lymphocytes. , 2021, 9, 251513552110171.	1.4	6
284	CircRNA-016901 silencing attenuates irradiation-induced injury in bone mesenchymal stem cells via regulating the miR-1249-5p/HIPK2 axis. Experimental and Therapeutic Medicine, 2021, 21, 355.	0.8	4
285	How I Manage: Pathophysiology and Management of Toxicity of Chimeric Antigen Receptor T-Cell Therapies. Journal of Clinical Oncology, 2021, 39, 456-466.	0.8	21
286	Therapeutic Options for Patients with TP53 Deficient Chronic Lymphocytic Leukemia: Narrative Review. Cancer Management and Research, 2021, Volume 13, 1459-1476.	0.9	3
287	Cytokine Release Syndrome Biology and Management. Cancer Journal (Sudbury, Mass ), 2021, 27, 119-125.	1.0	25
288	Research advances in chimeric antigen receptor-modified T-cell therapy (Review). Experimental and Therapeutic Medicine, 2021, 21, 484.	0.8	1
289	InÂvivo CART cell imaging: Paving the way for success in CART cell therapy. Molecular Therapy - Oncolytics, 2021, 20, 625-633.	2.0	14
290	Biomarkers for Predicting Cytokine Release Syndrome following CD19-Targeted CAR T Cell Therapy. Journal of Immunology, 2021, 206, 1561-1568.	0.4	36
291	Neurotoxicity Biology and Management. Cancer Journal (Sudbury, Mass ), 2021, 27, 126-133.	1.0	7
292	Current and future treatment strategies in chronic lymphocytic leukemia. Journal of Hematology and Oncology, 2021, 14, 69.	6.9	33
293	Pharmacologic Control of CAR T Cells. International Journal of Molecular Sciences, 2021, 22, 4320.	1.8	9
294	Reactions Related to CAR-T Cell Therapy. Frontiers in Immunology, 2021, 12, 663201.	2.2	54
295	Ibrutinib combinations in CLL therapy: scientific rationale and clinical results. Blood Cancer Journal, 2021, 11, 79.	2.8	36
296	Mechanisms of response and resistance to CAR T cell therapies. Current Opinion in Immunology, 2021, 69, 56-64.	2.4	18
297	Select Antitumor Cytotoxic CD8+ T Clonotypes Expand in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib. Clinical Cancer Research, 2021, 27, 4624-4633.	3.2	10
298	Is immunotherapy in the future of therapeutic management of sarcomas?. Journal of Translational Medicine, 2021, 19, 173.	1.8	18
299	How I treat chronic lymphocytic leukemia after venetoclax. Blood, 2021, 138, 361-369.	0.6	13

#	ARTICLE	IF	CITATIONS
300	Axicabtagene ciloleucel and brexucabtagene autoleucel in relapsed and refractory diffuse large B-cell and mantle cell lymphomas. <i>Future Oncology</i> , 2021, 17, 1269-1283.	1.1	20
301	Current State of CAR T-Cell Therapy in Chronic Lymphocytic Leukemia. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5536.	1.8	17
302	Using JAK inhibitor to treat cytokine release syndrome developed after chimeric antigen receptor T cell therapy for patients with refractory acute lymphoblastic leukemia. <i>Medicine (United States)</i> , 2021, 100, e25786.	0.4	10
303	Dual Effects of Cyclooxygenase Inhibitors in Combination With CD19.CAR-T Cell Immunotherapy. <i>Frontiers in Immunology</i> , 2021, 12, 670088.	2.2	10
304	Neurological complications of cancer immunotherapy (CAR T cells). <i>Journal of the Neurological Sciences</i> , 2021, 424, 117405.	0.3	10
305	Clinical Outcomes in Patients with Multi-Hit <i>TP53</i> Chronic Lymphocytic Leukemia Treated with Ibrutinib. <i>Clinical Cancer Research</i> , 2021, 27, 4531-4538.	3.2	20
306	Current Treatment Options in CLL. <i>Cancers</i> , 2021, 13, 2468.	1.7	20
307	Development of CAR T-cell lymphoma in 2 of 10 patients effectively treated with <i>piggyBac</i> -modified CD19 CAR T cells. <i>Blood</i> , 2021, 138, 1504-1509.	0.6	86
308	Mechanisms of Cardiovascular Toxicities Associated With Immunotherapies. <i>Circulation Research</i> , 2021, 128, 1780-1801.	2.0	48
310	Ibrutinib improves the efficacy of anti-CD19 CAR T cell therapy in patients with refractory non-Hodgkin lymphoma. <i>Cancer Science</i> , 2021, 112, 2642-2651.	1.7	23
311	Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. <i>Nature Reviews Immunology</i> , 2022, 22, 85-96.	10.6	315
313	BTK inhibitors, irrespective of ITK inhibition, increase efficacy of a CD19/CD3-bispecific antibody in CLL. <i>Blood</i> , 2021, 138, 1843-1854.	0.6	17
314	The Potential Role of the Intestinal Microenvironment and Individual Microbes in the Immunobiology of Chimeric Antigen Receptor T-Cell Therapy. <i>Frontiers in Immunology</i> , 2021, 12, 670286.	2.2	16
315	Melanoma reactive TCR-modified T cells generated without activation retain a less differentiated phenotype and mediate a superior in vivo response. <i>Scientific Reports</i> , 2021, 11, 13327.	1.6	8
316	CAR T-Cell Therapy in Hematologic Malignancies: Clinical Role, Toxicity, and Unanswered Questions. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2021, 41, e246-e265.	1.8	27
317	The "Magic Bullet" Is Here? Cell-Based Immunotherapies for Hematological Malignancies in the Twilight of the Chemotherapy Era. <i>Cells</i> , 2021, 10, 1511.	1.8	3
318	Risk Factors With Neurotoxicity After Chimeric Antigen Receptor T-Cell Therapy. <i>JAMA Neurology</i> , 2021, 78, 763.	4.5	1
319	ROR1 targeting with the antibody-drug conjugate VLS-101 is effective in Richter syndrome patient-derived xenograft mouse models. <i>Blood</i> , 2021, 137, 3365-3377.	0.6	47

#	ARTICLE	IF	CITATIONS
320	A Deep Insight Into CAR-T Cell Therapy in Non-Hodgkin Lymphoma: Application, Opportunities, and Future Directions. <i>Frontiers in Immunology</i> , 2021, 12, 681984.	2.2	32
321	Combining selective inhibitors of nuclear export (SINEs) with chimeric antigen receptor (CAR) T cells for CD19-positive malignancies. <i>Oncology Reports</i> , 2021, 46, .	1.2	12
322	Targeting Bruton's Tyrosine Kinase in CLL. <i>Frontiers in Immunology</i> , 2021, 12, 687458.	2.2	40
323	NK Cells in Chronic Lymphocytic Leukemia and Their Therapeutic Implications. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6665.	1.8	11
324	Current combinatorial CAR T cell strategies with Bruton tyrosine kinase inhibitors and immune checkpoint inhibitors. <i>Bone Marrow Transplantation</i> , 2021, 56, 2630-2636.	1.3	11
325	Is There a Role for Cellular Therapy in Chronic Lymphocytic Leukemia?. <i>Cancer Journal (Sudbury, Mass)</i> 10.784314. <a href="#">rgBT / Over</a>	1.0	1
326	Resistance to Bruton tyrosine kinase inhibitors: the Achilles heel of their success story in lymphoid malignancies. <i>Blood</i> , 2021, 138, 1099-1109.	0.6	14
327	Engineered T Cell Therapy for Gynecologic Malignancies: Challenges and Opportunities. <i>Frontiers in Immunology</i> , 2021, 12, 725330.	2.2	11
328	Development of a Clinically Relevant Reporter for Chimeric Antigen Receptor T-cell Expansion, Trafficking, and Toxicity. <i>Cancer Immunology Research</i> , 2021, 9, 1035-1046.	1.6	14
329	Treatment of Chronic Lymphocytic Leukemia After Discontinuation of Bruton's Tyrosine Kinase Inhibitors. <i>Hematology/Oncology Clinics of North America</i> , 2021, 35, 793-806.	0.9	1
330	Treatment-Related Adverse Events of Chimeric Antigen Receptor T-Cell (CAR T) in Clinical Trials: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2021, 13, 3912.	1.7	25
331	Hypermethylation of CD19 promoter enables antigen-negative escape to CART-19 in vivo and in vitro. , 2021, 9, e002352.		14
332	Chimeric antigen receptor T-cells (CARs) in cancer treatment. <i>Current Molecular Pharmacology</i> , 2021, 14, .	0.7	1
333	Immunomodulatory Drugs for the Treatment of B Cell Malignancies. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8572.	1.8	22
334	Engineering-enhanced CAR T cells for improved cancer therapy. <i>Nature Cancer</i> , 2021, 2, 780-793.	5.7	60
335	The Ongoing Unmet Needs in Chronic Lymphocytic Leukemia. <i>Hematology/Oncology Clinics of North America</i> , 2021, 35, 739-759.	0.9	1
336	Immune Therapy for Chronic Lymphocytic Leukemia. <i>Hematology/Oncology Clinics of North America</i> , 2021, 35, 847-862.	0.9	5
337	Engineering genetic devices for in vivo control of therapeutic T cell activity triggered by the dietary molecule resveratrol. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	16

#	ARTICLE	IF	CITATIONS
338	BET bromodomain protein inhibition reverses chimeric antigen receptor extinction and reinvigorates exhausted T cells in chronic lymphocytic leukemia. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	45
339	Cell therapy of chronic lymphocytic leukaemia: Transplants and chimeric antigen receptor (CAR)-T cells. <i>Blood Reviews</i> , 2021, 51, 100884.	2.8	1
340	Management of chimeric antigen receptor T-cell induced cytokine release syndrome: Current and emerging approaches. <i>Journal of Oncology Pharmacy Practice</i> , 2022, 28, 107815522110392.	0.5	1
341	Efficacy and safety of humanized CD19 CAR-T as a salvage therapy for recurrent CNSL of B-ALL following murine CD19 CAR-T cell therapy. <i>Oncology Letters</i> , 2021, 22, 788.	0.8	4
342	Revisiting Richter transformation in the era of novel CLL agents. <i>Blood Reviews</i> , 2021, 49, 100824.	2.8	19
343	CXCR5 guides migration and tumor eradication of anti-EGFR chimeric antigen receptor T cells. <i>Molecular Therapy - Oncolytics</i> , 2021, 22, 507-517.	2.0	17
344	Cellular Therapy. <i>Organ and Tissue Transplantation</i> , 2021, , 741-761.	0.0	0
345	Novel BCMA-OR-CD38 tandem-dual chimeric antigen receptor T cells robustly control multiple myeloma. <i>Oncolimmunology</i> , 2021, 10, 1959102.	2.1	19
346	CAR T Cells for Hematologic Malignancies. , 2021, , 829-846.		0
347	Hematopoietic versus Solid Cancers and T Cell Dysfunction: Looking for Similarities and Distinctions. <i>Cancers</i> , 2021, 13, 284.	1.7	15
348	The evolving role of Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia. <i>Therapeutic Advances in Hematology</i> , 2021, 12, 204062072198958.	1.1	13
349	Chimeric Antigen Receptor (CAR) T Cell Therapy for Cancer. Challenges and Opportunities: An Overview. <i>Methods in Molecular Biology</i> , 2021, 2174, 219-244.	0.4	7
351	Myeloma CAR-T CRS Management With IL-1R Antagonist Anakinra. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 632-636.e1.	0.2	31
352	Natural Killer Cell Hypo-responsiveness in Chronic Lymphocytic Leukemia can be Circumvented In Vitro by Adequate Activating Signaling. <i>HemaSphere</i> , 2019, 3, e308.	1.2	14
354	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events. , 2020, 8, e001511.		138
355	When better still might not be good enough. <i>Translational Cancer Research</i> , 2017, 6, S1244-S1247.	0.4	3
356	A Phase I clinical trial of chimeric antigen receptor-modified T cells in patients with relapsed and refractory lymphoma. <i>Immunotherapy</i> , 2020, 12, 681-696.	1.0	14
357	Relapse and Resistance to CAR-T Cells and Blinatumomab in Hematologic Malignancies. <i>Clinical Hematology International</i> , 2019, 1, 79.	0.7	15

#	ARTICLE	IF	CITATIONS
358	Genetically engineered CAR T-immune cells for cancer therapy: recent clinical developments, challenges, and future directions. <i>Journal of Applied Biomedicine</i> , 2019, 17, 11-11.	0.6	5
359	Cytokines in CAR T Cell-associated Neurotoxicity. <i>Frontiers in Immunology</i> , 2020, 11, 577027.	2.2	110
360	New actionable targets and investigational drugs in chronic lymphocytic leukemia. <i>Memo - Magazine of European Medical Oncology</i> , 0, , 1.	0.3	1
361	Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL. <i>Blood</i> , 2022, 139, 1794-1806.	0.6	66
362	Rejuvenating Effector/Exhausted CAR T Cells to Stem Cell Memory-like CAR T Cells By Resting Them in the Presence of CXCL12 and the NOTCH Ligand. <i>Cancer Research Communications</i> , 2021, 1, 41-55.	0.7	8
363	Driving Out Chronic Lymphocytic Leukemia With CAR T Cells. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 5-17.	0.6	4
364	Richter Transformation in Chronic Lymphocytic Leukemia: Update in the Era of Novel Agents. <i>Cancers</i> , 2021, 13, 5141.	1.7	16
365	Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures. <i>American Journal of Hematology</i> , 2021, 96, 1679-1705.	2.0	150
366	Restoration of the immune function as a complementary strategy to treat Chronic Lymphocytic Leukemia effectively. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 321.	3.5	15
367	Clinical Evaluation and Management of Chronic Lymphocytic Leukemia. , 2019, , 401-409.		0
368	Resistance to Bruton's Tyrosine Kinase Signaling Pathway Targeted Therapies. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2019, , 111-153.	0.1	1
370	Allogeneic hematopoietic cell transplantation and cellular therapy in CLL. <i>Onkologie (Czech)</i> Tj ETQq1 1 0.784314 ggBT /Overlock 10 Tf		0
372	Chronic Lymphocytic Leukemia with Alterations in TP53. , 2020, , 47-67.		0
373	Regional Gene Therapy for Cancer. , 2020, , 55-71.		0
374	Síndrome de neurotoxicidad asociada a células inmunoefectoras: un enfoque terapéutico en el paciente crítico. <i>Medicina Intensiva</i> , 2022, 46, 201-212.	0.4	2
375	Hypogammaglobulinemia After Chimeric Antigen Receptor (CAR) T-Cell Therapy: Characteristics, Management, and Future Directions. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 460-466.	2.0	24
378	Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy. <i>Blood Advances</i> , 2022, 6, 2055-2068.	2.5	60
379	Phase I study of CBM.CD19 chimeric antigen receptor T cell in the treatment of refractory diffuse large B-cell lymphoma in Chinese patients. <i>Frontiers of Medicine</i> , 2021, , 1.	1.5	1

#	ARTICLE	IF	CITATIONS
380	Engineered CAR-T and novel CAR-based therapies to fight the immune evasion of glioblastoma: gutta cavat lapidem. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 1333-1353.	1.1	9
381	A comprehensive analysis of the fatal toxic effects associated with CD19 CAR-T cell therapy. <i>Aging</i> , 2020, 12, 18741-18753.	1.4	19
382	The use of chimeric antigen receptor T cells in patients with non-Hodgkin lymphoma. <i>Clinical Advances in Hematology and Oncology</i> , 2018, 16, 375-386.	0.3	15
385	AssociaÃ§Ã£o Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. III: anti-CD19 CAR-T cell therapy for patients with non-Hodgkin lymphoma. <i>Hematology, Transfusion and Cell Therapy</i> , 2021, 43, S22-S29.	0.1	0
386	Benign tumors in TSC are amenable to treatment by GD3 CAR T cells in mice. <i>JCI Insight</i> , 2021, 6, .	2.3	5
387	T Cell Fitness and Autologous CAR T Cell Therapy in Haematologic Malignancy. <i>Frontiers in Immunology</i> , 2021, 12, 780442.	2.2	42
388	Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial. <i>Lancet Haematology</i> , 2021, 8, e879-e890.	2.2	48
390	Use of CAR T-cell for acute lymphoblastic leukemia (ALL) treatment: a review study. <i>Cancer Gene Therapy</i> , 2022, 29, 1080-1096.	2.2	52
391	Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS). , 2022, 10, e003847.		44
393	Treatment Approaches to Chronic Lymphocytic Leukemia With High-Risk Molecular Features. <i>Frontiers in Oncology</i> , 2021, 11, 780085.	1.3	4
394	Enhanced Chimeric Antigen Receptor T Cell Therapy through Co-Application of Synergistic Combination Partners. <i>Biomedicines</i> , 2022, 10, 307.	1.4	9
395	Resistance and recurrence of malignancies after CAR-T cell therapy. <i>Experimental Cell Research</i> , 2022, 410, 112971.	1.2	4
396	IL-6/IFN- $\gamma$ double knockdown CAR-T cells reduce the release of multiple cytokines from PBMCs in vitro. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-14.	1.4	12
397	CLL update 2022: A continuing evolution in care. <i>Blood Reviews</i> , 2022, 54, 100930.	2.8	24
398	Management of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in the Era of Targeted Therapies. <i>Current Hematologic Malignancy Reports</i> , 2022, 17, 39-45.	1.2	0
399	The Role of Bruton's Kinase Inhibitors in Chronic Lymphocytic Leukemia: Current Status and Future Directions. <i>Cancers</i> , 2022, 14, 771.	1.7	35
400	Decade-long leukaemia remissions with persistence of CD4+ CAR T cells. <i>Nature</i> , 2022, 602, 503-509.	13.7	369
401	Chronic Lymphocytic Leukaemia. , 2022, , 79-82.		2

#	ARTICLE	IF	CITATIONS
402	Methods to monitor in vivo expansion and efficacy of CAR-T cells in preclinical models. <i>Methods in Cell Biology</i> , 2022, 167, 185-201.	0.5	0
403	Adoptive T-cell Immunotherapy: Perfecting Self-Defenses. <i>Experientia Supplementum (2012)</i> , 2022, 113, 253-294.	0.5	1
404	Delivery strategies in treatments of leukemia. <i>Chemical Society Reviews</i> , 2022, 51, 2121-2144.	18.7	17
405	Cellular Therapy Advances in Chronic Lymphocytic Leukemia and Richter's Syndrome. <i>Current Problems in Cancer</i> , 2022, 46, 100827.	1.0	1
406	Immunotherapeutic Strategies in Chronic Lymphocytic Leukemia: Advances and Challenges. <i>Frontiers in Oncology</i> , 2022, 12, 837531.	1.3	10
407	Clinical outcome of allogeneic stem cell transplantation in patients with B-cell lymphoid malignancies following treatment with targeted small molecule inhibitors. <i>Leukemia and Lymphoma</i> , 2022, , 1-9.	0.6	2
408	Immune effector cell-associated neurotoxicity syndrome: A therapeutic approach in the critically ill. <i>Medicina Intensiva (English Edition)</i> , 2022, , .	0.1	2
409	Results of <scp>ARI</scp>â€œ0001 <scp>CART19</scp> cell therapy in patients with relapsed/refractory <scp>CD19</scp>â€œpositive acute lymphoblastic leukemia with isolated extramedullary disease. <i>American Journal of Hematology</i> , 2022, 97, 731-739.	2.0	6
410	Development and validation of liquid chromatography method for determination of Ibrutinib in finished dosage forms using quality by design approach. <i>Separation Science Plus</i> , 2022, 5, 254-266.	0.3	16
411	Biology and Treatment of Richter Transformation. <i>Frontiers in Oncology</i> , 2022, 12, 829983.	1.3	22
412	Novel Approaches for the Treatment of Patients with Richterâ€™s Syndrome. <i>Current Treatment Options in Oncology</i> , 2022, 23, 526-542.	1.3	4
413	Comparison of single copy geneâ€œbased duplex quantitative PCR and digital droplet PCR for monitoring of expansion of CD19â€œdirected CAR T cells in treated patients. <i>International Journal of Oncology</i> , 2022, 60, .	1.4	5
414	Recent Advances in CAR T-Cell Therapy for Patients with Chronic Lymphocytic Leukemia. <i>Cancers</i> , 2022, 14, 1715.	1.7	9
415	Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia. <i>Blood Advances</i> , 2022, 6, 5774-5785.	2.5	43
416	CRISPR Gene Editing of Human Primary NK and T Cells for Cancer Immunotherapy. <i>Frontiers in Oncology</i> , 2022, 12, 834002.	1.3	8
417	Richterâ€™s Transformation. <i>Current Oncology Reports</i> , 2022, 24, 1081-1090.	1.8	6
418	Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 387-405.	2.3	124
419	Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 367.	3.5	72



#	ARTICLE	IF	CITATIONS
420	Importance of T, NK, CAR T and CAR NK Cell Metabolic Fitness for Effective Anti-Cancer Therapy: A Continuous Learning Process Allowing the Optimization of T, NK and CAR-Based Anti-Cancer Therapies. <i>Cancers</i> , 2022, 14, 183.	1.7	8
421	Preclinical Evaluation of CD64 As a Potential Target For CAR-T-cell Therapy For Acute Myeloid Leukemia. <i>Journal of Immunotherapy</i> , 2022, 45, 67-77.	1.2	6
422	Acoustofluidic-mediated molecular delivery to human T cells with a three-dimensional-printed flow chamber. <i>Journal of the Acoustical Society of America</i> , 2021, 150, 4534-4547.	0.5	5
423	CAR T-cell immunotherapy: a powerful weapon for fighting hematological B-cell malignancies. <i>Frontiers of Medicine</i> , 2021, 15, 783-804.	1.5	3
424	Development of CAR T Cell Therapy in Children—A Comprehensive Overview. <i>Journal of Clinical Medicine</i> , 2022, 11, 2158.	1.0	12
425	Long-term outcomes for ibrutinib+rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial. <i>Blood</i> , 2022, 140, 112-120.	0.6	93
426	Chronic Lymphocytic Leukemia: Chemotherapy Free and Other Novel Therapies Including CAR T. <i>Current Treatment Options in Oncology</i> , 2022, 23, 904.	1.3	4
427	Modulating tumor physical microenvironment for fueling CAR-T cell therapy. <i>Advanced Drug Delivery Reviews</i> , 2022, 185, 114301.	6.6	28
456	SOHO State of the Art Updates and Next Questions   Management of Most Difficult Cases of Chronic Lymphocytic Leukemia: Relapse After Both BTK and BCL2 Inhibition and Richter Transformation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 427-435.	0.2	2
457	In-situ scalable manufacturing of Epstein-Barr virus-specific T-cells using bioreactor with an expandable culture area (BECA). <i>Scientific Reports</i> , 2022, 12, 7045.	1.6	1
458	Cellular Therapy in High-Risk Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter Syndrome. <i>Frontiers in Oncology</i> , 2022, 12, 888109.	1.3	2
459	Demographic differences among patients treated with chimeric antigen receptor <sc>T cell</sc> therapy in the United States. <i>Cancer Medicine</i> , 2022, 11, 4440-4448.	1.3	6
460	CAR T cell manufacturing from naive/stem memory T lymphocytes enhances antitumor responses while curtailing cytokine release syndrome. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	66
461	Bispecific Antibody-Bound T Cells as a Novel Anticancer Immunotherapy. <i>Biomolecules and Therapeutics</i> , 2022, 30, 418-426.	1.1	2
462	Time to evolve: predicting engineered T cell-associated toxicity with next-generation models. , 2022, 10, e003486.		21
463	Developing lisocabtagene maraleucel chimeric antigen receptor T-cell manufacturing for improved process, product quality and consistency across CD19+ hematologic indications. <i>Cytotherapy</i> , 2022, 24, 962-973.	0.3	6
464	BTK Inhibitors and CAR T-Cell Therapy in Treating Mantle Cell Lymphoma—Finding a Dancing Partner. <i>Current Oncology Reports</i> , 2022, 24, 1299-1311.	1.8	10
465	Cardiovascular Toxicities with Chimeric Antigen Receptor T-cell Therapy. <i>Current Cardiology Reviews</i> , 2022, 18, .	0.6	1



#	ARTICLE	IF	CITATIONS
466	CAR T Cell Therapy in Hematological Malignancies: Implications of the Tumor Microenvironment and Biomarkers on Efficacy and Toxicity. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6931.	1.8	3
467	Chimeric antigen receptor T cells and management of toxicities: implications of biomarkers. , 2022, , 245-281.		0
468	Influence of Culture Conditions on Ex Vivo Expansion of T Lymphocytes and Their Function for Therapy: Current Insights and Open Questions. <i>Frontiers in Bioengineering and Biotechnology</i> , 0, 10, .	2.0	4
469	Interleukin Inhibitors in Cytokine Release Syndrome and Neurotoxicity Secondary to CAR-T Therapy. <i>Diseases (Basel, Switzerland)</i> , 2022, 10, 41.	1.0	6
470	Evaluating the Therapeutic Potential of Idecabtagene Vicleucel in the Treatment of Multiple Myeloma: Evidence to Date. <i>OncoTargets and Therapy</i> , 0, Volume 15, 799-813.	1.0	3
471	Enhanced Costimulatory Signaling Improves CAR T-cell Effector Responses in CLL. <i>Cancer Research Communications</i> , 2022, 2, 1089-1103.	0.7	3
472	CAR-NK Cells: A Chimeric Hope or a Promising Therapy?. <i>Cancers</i> , 2022, 14, 3839.	1.7	15
473	CAR T-Based Therapies in Lymphoma: A Review of Current Practice and Perspectives. <i>Biomedicines</i> , 2022, 10, 1960.	1.4	5
474	Effects of ibrutinib on T-cell immunity in patients with chronic lymphocytic leukemia. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
476	Pneumococcal Conjugate Vaccine Does Not Induce Humoral Response When Administrated Within the Six Months After CD19 CAR T-Cell Therapy. <i>Transplantation and Cellular Therapy</i> , 2023, 29, 277.e1-277.e9.	0.6	9
477	Emerging Therapies for the Management of Richter Transformation. <i>Journal of Clinical Oncology</i> , 2023, 41, 395-409.	0.8	10
478	Clinical Strategies for Enhancing the Efficacy of CAR T-Cell Therapy for Hematological Malignancies. <i>Cancers</i> , 2022, 14, 4452.	1.7	1
479	The risk factors and early predictive model of hematotoxicity after CD19 chimeric antigen receptor T cell therapy. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
480	The journey of CAR-T therapy in hematological malignancies. <i>Molecular Cancer</i> , 2022, 21, .	7.9	45
481	Digital polymerase chain reaction strategies for accurate and precise detection of vector copy number in chimeric antigen receptor T-cell products. <i>Cytotherapy</i> , 2023, 25, 94-102.	0.3	2
482	Tumor buster - where will the CAR-T cell therapy "missile" go?. <i>Molecular Cancer</i> , 2022, 21, .	7.9	23
483	Impact of the selective A2AR and A2BR dual antagonist AB928/etrumadenant on CAR T cell function. <i>British Journal of Cancer</i> , 2022, 127, 2175-2185.	2.9	11
485	Safety switch optimization enhances antibody-mediated elimination of CAR T cells. <i>Frontiers in Molecular Medicine</i> , 0, 2, .	0.6	1

#	ARTICLE	IF	CITATIONS
487	CAR T Cell Immunotherapy That Revolutionary Breakthrough in Human Oncology Treatment: A Review. <i>Pharmacology &amp; Pharmacy</i> , 2022, 13, 483-515.	0.2	0
488	A novel polymer-conjugated human IL-15 improves efficacy of CD19-targeted CAR T-cell immunotherapy. <i>Blood Advances</i> , 2023, 7, 2479-2493.	2.5	4
489	Switchable targeting of solid tumors by BsCAR T cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	13
490	Learning from TCR Signaling and Immunological Synapse Assembly to Build New Chimeric Antigen Receptors (CARs). <i>International Journal of Molecular Sciences</i> , 2022, 23, 14255.	1.8	8
492	EEG-based grading of immune effector cell-associated neurotoxicity syndrome. <i>Scientific Reports</i> , 2022, 12, .	1.6	0
493	Dose-response correlation for CAR-T cells: a systematic review of clinical studies. , 2022, 10, e005678.		15
494	Phase I CAR-T Clinical Trials Review. <i>Anticancer Research</i> , 2022, 42, 5673-5684.	0.5	0
496	Evaluating the Patient with Neurotoxicity after Chimeric Antigen Receptor T-cell Therapy. <i>Current Treatment Options in Oncology</i> , 2022, 23, 1845-1860.	1.3	2
497	Novel therapies and combinations in CLL refractory to BTK inhibitors and venetoclax. <i>Hematology American Society of Hematology Education Program</i> , 2022, 2022, 316-322.	0.9	4
498	Chimeric antigen receptor T cell therapy in multiple myeloma: A comprehensive review of current data and implications for clinical practice. <i>Ca-A Cancer Journal for Clinicians</i> , 2023, 73, 275-285.	157.7	24
499	CD4 CAR-T cells targeting CD19 play a key role in exacerbating cytokine release syndrome, while maintaining long-term responses. , 2023, 11, e005878.		11
500	CTP synthase 2 predicts inferior survival and mediates DNA damage response via interacting with BRCA1 in chronic lymphocytic leukemia. <i>Experimental Hematology and Oncology</i> , 2023, 12, .	2.0	2
501	Canadian evidence-based guideline for frontline treatment of chronic lymphocytic leukemia: 2022 update. <i>Leukemia Research</i> , 2023, 125, 107016.	0.4	6
502	Barnase-barstar Specific Interaction Regulates Car-T Cells Cytotoxic Activity toward Malignancy. <i>Doklady Biochemistry and Biophysics</i> , 0, , .	0.3	1
503	CAR-T cells for cancer immunotherapy. <i>Chinese Chemical Letters</i> , 2023, 34, 108202.	4.8	3
504	A second-generation CD38-CAR T cell for the treatment of multiple myeloma. <i>Cancer Medicine</i> , 0, , .	1.3	1
505	Challenges and opportunities of CAR T-cell therapies for CLL. <i>Seminars in Hematology</i> , 2023, 60, 25-33.	1.8	3
506	A systematic framework for predictive biomarkers in immune effector cell-associated neurotoxicity syndrome. <i>Frontiers in Neurology</i> , 0, 14, .	1.1	4

#	ARTICLE	IF	CITATIONS
507	Emerging Therapies in CLL in the Era of Precision Medicine. <i>Cancers</i> , 2023, 15, 1583.	1.7	4
508	Cellular therapies: Hematology and beyond. <i>Seminars in Hematology</i> , 2023, 60, 1-2.	1.8	0
509	Systemsâ€based digital twins to help characterize clinical <scp>doseâ€response</scp> and propose predictive biomarkers in a Phase I study of bispecific antibody, mosunetuzumab, in <scp>NHL</scp>. <i>Clinical and Translational Science</i> , 2023, 16, 1134-1148.	1.5	8
510	Cellular Therapies in Chronic Lymphocytic Leukemia and Richterâ€™s Transformation: Recent Developments in Chimeric Antigen Receptor T-Cells, Natural Killer Cells, and Allogeneic Stem Cell Transplant. <i>Cancers</i> , 2023, 15, 1838.	1.7	3
511	Treatment of Richter Transformation of Chronic Lymphocytic Leukemia in the Modern Era. <i>Cancers</i> , 2023, 15, 1857.	1.7	3
512	Empowering the Potential of CAR-T Cell Immunotherapies by Epigenetic Reprogramming. <i>Cancers</i> , 2023, 15, 1935.	1.7	2
513	Clinical and molecular overview of immunotherapeutic approaches for malignant skin melanoma: Past, present and future. <i>Critical Reviews in Oncology/Hematology</i> , 2023, 186, 103988.	2.0	2
522	Hematopoietic Cell Transplantation and Other Cellular Therapies for Chronic Lymphocytic Leukemia. , 2024, , 247-261.		0
532	Lymph node metastasis in cancer progression: molecular mechanisms, clinical significance and therapeutic interventions. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	4
540	Mechanisms of ferroptosis and targeted therapeutic approaches in lymphoma. <i>Cell Death and Disease</i> , 2023, 14, .	2.7	0
557	CAR-T immunotherapy for hematologic cancers: restrictions and potential strategies. , 2024, , .		0
559	Molecular diagnosis, drivers, and treatment modalities for chronic lymphocytic leukemia. , 2024, , 235-248.		0